Although using adenovirus and the Cav-1 scaffolding domain peptide are good approaches to determine the ability of Cav-1 to decrease fibrogenesis and pathogenesis of pulmonary fibrosis in an animal model, it would be beneficial to IPF patients that an approach can provide the ease and simplicity of administration, leading to safe, efficient and reproducible Cav-1 expression. Here, CAV1 is linked to idiopathic pulmonary fibrosis.